Boston Scientific Corp. (BSX) Tops Q3 EPS by 6c; Adjusts FY11 Outlook, Guides Q411
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts BSX Hot Sheet
Price: $45.69 -0.7%
Revenue Growth %: +1.0%
Financial Fact:
Operating income (loss): 348M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +1.0%
Financial Fact:
Operating income (loss): 348M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Boston Scientific Corp. (NYSE: BSX) reported Q3 EPS of $0.15, $0.06 better than the analyst estimate of $0.09. Revenue for the quarter came in at $1.87 billion versus the consensus estimate of $1.91 billion.
Boston Scientific Corp. sees Q4 2011 EPS of $0.13-$0.16, versus the consensus of $0.10. Boston Scientific Corp. sees Q4 2011 revenue of $1.85-$1.95 billion, versus the consensus of $1.97 billion.
Boston Scientific Corp. sees FY2011 EPS of $0.67-$0.70, versus prior guidance of $0.64-$0.70 and the consensus of $0.45. Boston Scientific Corp. sees FY2011 revenue of $7.624-$7.724 billion, versus the consensus of $7.77 billion.
Boston Scientific Corp. sees Q4 2011 EPS of $0.13-$0.16, versus the consensus of $0.10. Boston Scientific Corp. sees Q4 2011 revenue of $1.85-$1.95 billion, versus the consensus of $1.97 billion.
Boston Scientific Corp. sees FY2011 EPS of $0.67-$0.70, versus prior guidance of $0.64-$0.70 and the consensus of $0.45. Boston Scientific Corp. sees FY2011 revenue of $7.624-$7.724 billion, versus the consensus of $7.77 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- Rogers Communications (RCI) Tops Q3 EPS by 42c
- TD Cowen on Boston Scientific (BSX): 'Cyberattack To Weigh on Q3 Results; We Remain Bullish on the Setup for 2027'
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
